Share: Share on Facebook Share on Twitter Share on LinkedIn I recommend visiting cushmanwakefield.com to read:%0A%0A {0} %0A%0A {1}

Cushman & Wakefield Awarded QIAGEN Citylabs 2.0 Brief

16/09/2020

QIAGEN, a global leader in Sample to Insight solutions for molecular testing has appointed Cushman & Wakefield to provide Project & Development Services for its £35m new base in Manchester.

The firm will be acting as Project Managers, Cost Consultants, Mechanical and Electrical Consultants and Health and Safety Advisor to deliver the Cat A and B fit out for QIAGEN’s European Hub for Diagnostics Development, part of the Citylabs 2.0 development in Manchester.

QIAGEN has pre-let 92,000 sq ft, including life science laboratories and 40,000 sq ft of support office space, at the scheme which is due for completion in spring 2021. QIAGEN’s relocation from its current base at Manchester Science Park will see them become the anchor industrial partner in the genomics campus.

Citylabs 2.0 is the first phase of a £60m extension of the genomics campus for Manchester Science Partnerships (MSP) in a joint venture with Manchester University NHS Foundation Trust (MFT). It is located within Europe’s largest clinical academic campus and is surrounded by the Manchester Royal Infirmary, Royal Manchester Children’s Hospital, Saint Mary’s Hospital and Manchester Royal Eye Hospital.

Gareth Collins-Jones, Head of Northern Project Management at Cushman & Wakefield, said: “We are delighted to have been commissioned to provide full construction related services to our globally renowned client QIAGEN on this major European hub for Research and Development in life science.

“Our focus is to deliver a highly technical and exceptional workplace on time and within our client’s budget and work with the many outside stakeholders of the development including NHS and Manchester Science Park. We will complete this significant project in spring 2021 and enable a smooth transitional phased move from the current research facility whilst maintaining ongoing research projects.”  

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. It provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2020, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. The company currently has about 270 employees in Manchester and is committed to further growth.

MEDIA CONTACT

Richard Coleman, Head of Communications EMEA
Richard Coleman

Head of EMEA Communications • London

What's new

Marcus Wood
Marcus Wood Rejoins Cushman & Wakefield as Head of Retail Capital Markets

Marcus Wood has rejoined Cushman & Wakefield as Head of UK Retail Capital Markets.

13/12/2021

What's Next for Offices Post-Event
What's Next for Offices Post-Event

Our virtual event, What’s Next for Offices, invited Derwent London, Pearson plc, HB Reavis along with other workplace specialists, to explore changes in the office sector, make predictions for the market and discuss the role of offices in building a sustainable future.

Ben Cullen • 09/11/2021

The Rise and Rise of ASEAN
Cushman & Wakefield Research Shows EMEA Prime Logistics Yields Close To Converging On Retail

The rampant growth in rents across the logistics sector continues amid a broader recovery in markets as the impacts of the COVID-19 pandemic begin to wane, according to Cushman & Wakefield’s latest DNA of Real Estate research for Q3 2021.

Richard Coleman • 08/11/2021

CAN'T FIND WHAT YOU'RE LOOKING FOR?

Get in touch with one of our professionals.
With your permission we and our partners would like to use cookies in order to access and record information and process personal data, such as unique identifiers and standard information sent by a device to ensure our website performs as expected, to develop and improve our products, and for advertising and insight purposes.

Alternatively click on More Options and select your preferences before providing or refusing consent. Some processing of your personal data may not require your consent, but you have a right to object to such processing.

You can change your preferences at any time by returning to this site or clicking on Cookies.
MORE OPTIONS
Agree and Close
These cookies ensure that our website performs as expected,for example website traffic load is balanced across our servers to prevent our website from crashing during particularly high usage.
These cookies allow our website to remember choices you make (such as your user name, language or the region you are in) and provide enhanced features. These cookies do not gather any information about you that could be used for advertising or remember where you have been on the internet.
These cookies allow us to work with our marketing partners to understand which ads or links you have clicked on before arriving on our website or to help us make our advertising more relevant to you.
AGREE ALL
REJECT ALL
SAVE SETTINGS